Symptom Management Note (Pain and Opioids)

Symptom Management Note – Pain and Opioid Management

Date: [Date]

Patient: [Patient name/identifier]

Provider: [Provider name, credentials]

Visit Type: [initial evaluation / follow-up]

Data Sources: [patient / caregiver / chart review / PDMP / outside records] (Select all that apply.)

Chief Concern

[Reason for pain/opioid-focused visit] (Limit to 1–2 lines.)

Subjective

[Visit context] (For follow-ups: interval history since last visit, major changes, hospitalizations, patient priorities for today. For initial visits: referral context and goals.)

[Pain characterization narrative] (Synthesize into one paragraph: location and radiation; intensity on consistent scale for current/average/worst; quality descriptors; temporal pattern including breakthrough episodes; onset and duration; aggravating and alleviating factors; associated symptoms. If patient denies pain, document "pain screen negative" and omit detailed characterization.)

Functional impact and goals: [Interference with activity, sleep, mood, work, mobility, self-care; 1–3 patient-centered functional goals in patient's own words]

Current analgesic regimen:

• [Opioid medications: name, formulation, dose, frequency, scheduled vs PRN, typical daily use, effectiveness, duration of relief, adverse effects] (Add lines as needed.)
• [Non-opioid analgesics tried and response, including reasons for discontinuation]
• [Non-pharmacologic modalities and response]

Opioid safety screen: (Include when opioids are current or being considered.)

• [Prior opioid trials and reasons stopped; history of overdose or naloxone use]
• [Concurrent CNS depressants: benzodiazepines, sedatives, alcohol, gabapentinoids]
• [Risk-relevant comorbidities: respiratory disease, sleep apnea, renal/hepatic impairment, frailty/falls]
• [Mental health and substance use screen with pertinent positives and negatives]
• [Safe storage and disposal considerations]

Constipation and opioid adverse effects:

• [Bowel pattern: baseline, current frequency/consistency, current regimen and response]
• [Sedation, cognitive effects, nausea, other relevant effects] (Include only if present or actively screened.)

Objective

Vitals: [BP, HR, RR, SpO2, Temp, Weight as relevant] (Include respiratory rate when sedation is a concern.)

Exam: [General appearance and distress level; mental status and alertness; respiratory effort; pertinent MSK/neurologic findings for pain syndrome; abdominal exam if constipation/obstruction concern] (Omit elements not performed.)

Safety Data Review:

• PDMP: [Reviewed on date with key findings / Not reviewed with reason] (Always document status explicitly.)
• Toxicology/UDS: [Date, expected vs unexpected findings, interpretation / Not performed with reason]
• Pertinent labs: [Renal/hepatic function, other relevant results] (Include only if relevant to dosing or safety.)

Assessment

[Synthesis paragraph: pain syndrome type and suspected etiology; current functional burden relative to patient goals; opioid benefit vs harm assessment; key safety risks and protective factors] (If opioids are continued, initiated, or changed, explicitly state this represents a deliberate risk–benefit decision.)

• [Problem 1 – highest priority: brief status]
• [Problem 2: brief status]
• [Additional problems as needed] (List in descending clinical priority. Include opioid-induced adverse effects and safety risks when present.)

Plan

(Organize by problem. Use Start/Stop/Continue/Change verbs. Place non-pharmacologic and non-opioid strategies first.)

[Problem 1]: [Pain syndrome]

• Non-pharmacologic: [Interventions, instructions, expected functional benefit]
• Non-opioid medications: [Start/Stop/Continue/Change: medication, dose, frequency, rationale]
• Opioid decision: [Indicated / Not indicated] (Justify with functional goals; list specific risks considered; define parameters triggering change.)
• Opioid regimen: [Start/Stop/Continue/Change: name, formulation, dose, frequency, scheduled vs PRN, maximum daily dose, breakthrough plan] (Include only if opioids prescribed.)
• Opioid conversion: [Reason for rotation; current opioid exposure; equianalgesic calculation with reference; cross-tolerance reduction % and rationale; new regimen with dose limits; transition monitoring plan] (Include only if changing opioid or route.)

[Problem 2]: [Additional problem]

• [Plan details] (Include only if applicable.)

Adverse Effect Prevention

• Constipation prophylaxis: [Bowel regimen, escalation criteria, red-flag instructions] (Required when opioids are prescribed.)
• Other effects: [Nausea plan, sedation precautions, falls mitigation] (Include as relevant.)

Safety and Education

• Counseling provided: [Take as prescribed; avoid alcohol/sedatives; driving restrictions; safe storage and disposal]
• Naloxone status: [Discussed / Prescribed / Already available / Declined with reason] (Always document explicitly.)
• Risk mitigation: [Coordination with other prescribers if applicable; other safety measures]

Monitoring and Follow-up

Follow-up: [Interval and modality] (Default 1–4 weeks when initiating or escalating. Always document explicitly.)

• Reassess: [Pain, functional goals, adverse effects, adherence patterns]
• PDMP/UDS plan: [Frequency, next UDS due date]
• Refill parameters: [Quantity, early refill policy, lost/stolen contingency] (Include if applicable.)
• Return precautions: [Respiratory depression, severe confusion, severe constipation, uncontrolled pain, new neurologic deficits]